Kavora

Research records · policy context · safety signals

Trials & Results Hub

A structured place to follow publicly visible ibogaine and noribogaine trial activity, what each study is designed to measure, and where its results can—or cannot—be checked.

For wider context on changing policy, safety, and treatment claims, begin with Kavora’s evidence-first ibogaine resource. This page separates a registry entry from a result, and a result from a conclusion.

Phase 1–3 Ibogaine & noribogaine Public records only
Quiet clinical setting illustrating careful review of ibogaine trial evidence

01 / Start with the record

What a trial listing can actually tell you

A trial record commonly identifies the sponsor, condition under study, recruiting status, planned enrollment, primary outcome measures, and locations. It does not by itself establish that an intervention works, is safe, or is available as ordinary care.

Registries are the first checkpoint

The U.S. National Library of Medicine maintains ClinicalTrials.gov trial records, where posted fields can be checked against a study’s stated design and updates. For studies conducted in the European Union, the EU clinical trials register is another public point of reference.

Ibogaine is a psychoactive alkaloid associated with Tabernanthe iboga, while noribogaine is a metabolite frequently discussed in development programs. A study’s name, formulation, dose, eligibility rules, and monitoring plan all matter; none should be assumed from a broad label alone.

When a listing is complete, compare the protocol’s primary endpoints with any posted results. When no results are posted, describe the record as incomplete rather than treating promotional language as a substitute for data.

02 / Study fields

Read a study beyond its headline

Use a consistent set of fields for active and completed records. The aim is not to turn a registry into a verdict, but to make its limits visible.

Identifier & sponsor

Who owns the protocol?

Record the registry identifier and named sponsor. Those details help distinguish a registered protocol from claims that do not identify a traceable study record.

Status & indication

What is being studied?

Note whether the entry is recruiting, active but not recruiting, completed, withdrawn, terminated, or has an unknown status—and the specific indication named by the protocol.

Endpoints & results

What was measured?

Primary endpoints, timing, and analysis plans set the frame for interpretation. Results may be peer-reviewed, preprint-only, sponsor-reported, posted in a registry, or unavailable.

Detail view suggesting close review of study outcomes and safety documentation

03 / Completed studies

A result needs its denominator, endpoint, and safety context

For a completed trial, a useful summary identifies the enrolled or analyzed sample size, the primary outcome, the time point, reported adverse events, and the form in which findings are available. A sponsor release can signal an update, but it is not equivalent to a full peer-reviewed paper or a posted statistical results table.

In particular, cardiac safety deserves direct attention. The U.S. Food and Drug Administration explains that QT interval prolongation can be associated with abnormal heart rhythms; individual trial materials should therefore be read for their actual screening, electrocardiogram, exclusion, and adverse-event reporting rather than assumed safe from a general description.

  • 01Primary outcome: Report the stated endpoint and measure, not a broader benefit claim.
  • 02Sample and timing: State the analyzed population and follow-up window when publicly available.
  • 03Safety signals: Preserve uncertainty around adverse events, discontinuations, and missing follow-up.
  • 04Publication status: Mark findings as peer-reviewed, preprint, registry-posted, sponsor-reported, or unavailable.

Interpretation note

“A registered trial is a question being tested—not an answer already earned.”
Why the distinction matters

Study design, missing results, small samples, safety exclusions, and follow-up limits can all change what a finding can support. Keep the public record, the reported result, and the unresolved questions visibly separate.

04 / Context around trial claims

Adjacent questions often travel with the research

A trial update may prompt questions about cognition, naming, access, costs, and cross-border services. These topics need their own evidence and should not be folded into the interpretation of one study.

Brain aging and cognition

Questions about cognitive decline deserve careful separation from registered endpoints. Review ibogaine and Alzheimer’s discussions alongside the narrower claims a protocol is actually built to test.

Terms can obscure substance identity

Different labels can make a record harder to find or compare. A guide to other names used for ibogaine can help readers identify terminology without treating names as evidence of equivalence.

Access is not trial enrollment

A search for treatment options is different from eligibility for a monitored research protocol. Keep that boundary clear when evaluating ibogaine treatment centers near a location.

Costs are not outcome data

Financial comparisons can be important to a family, but they do not validate safety or efficacy. Consider practical questions about the cost of ibogaine treatment separately from an investigator’s reported endpoints.

05 / Common questions

How to use this hub without overreading it

Public records can improve transparency, but they do not replace medical, legal, or individualized safety advice.

Does a completed trial mean the treatment is established?

No. Completion describes a study status. Look for the prespecified primary outcome, sample size, safety reporting, and whether a full result is publicly available. The safety and screening questions provide separate context for high-risk decision-making.

What if the registry lists no public results?

State that results are unavailable or restricted in the public record. It is appropriate to note a sponsor announcement if one exists, but not to fill missing methods or outcomes with inference. The regulatory tracker can help keep legal developments distinct from clinical findings.

Can clinic marketing be used as a trial result?

No. Marketing pages and trial registries serve different purposes. If assessing claims about a best ibogaine treatment clinic or comparing ibogaine clinics in Costa Rica, look for clearly identified evidence and do not assume it corresponds to a registered protocol.

Where does broader brain-aging discussion fit?

It belongs in a separate evidence review. The material on ibogaine and brain aging should be read as a distinct topic, not as proof of the outcome of an individual ibogaine or noribogaine trial.

Keep the categories separate

Research status, policy status, and care claims are not interchangeable.

Use the trial record as a starting point, then compare its public evidence with the broader questions covered in Kavora’s information pathways.

How Kavora approaches evidence